• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

PACE Trial and PACE Trial Protocol

Esther12

Senior Member
Messages
13,774
(Not a recommendation)
The PACE Trial investigators have produced a new FAQ. It is full of spin:
http://www.wolfson.qmul.ac.uk/current-projects/pace-trial/#faq

They seem to be annoyed that they keep having to repeat rubbish excuses for their quackery as no-one believes them.

Once again it's less than clear who it is that's frequently asking these questions, that side-step many of the key concerns raised by the trial's critics and seem designed to serve the propaganda aims of the trial's researchers, but we're used to that by now.

I'm not sure if it's worth going through and picking them apart in detail at this point.
 
Last edited:

Dolphin

Senior Member
Messages
17,567
(Not a recommendation)
The PACE Trial investigators have produced a new FAQ. It is full of spin:
http://www.wolfson.qmul.ac.uk/current-projects/pace-trial/#faq
After an editorial suggested that having scores within the normal population range was consistent with recovery, the authors published a correction to clarify that this was not the case.

Are they referring to the editorial by Bleijenberg and Knoop in February 2011? Because this was published in 2015.

Also it is not in the form of correction but is a response to letters replying to a 2015 paper.

And it doesn't deal with the point it claims to correct.

Maybe the worst correction ever?

http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(15)00114-5/fulltext

Volume 2, No. 4, e10–e11, April 2015

Methods and outcome reporting in the PACE trial–Author's
reply


DOI: http://dx.doi.org/10.1016/S2215-0366(15)00114-5

We did a randomised controlled trial (n=640) and found two rehabilitative treatments, graded exercise therapy (GET) and cognitive behaviour therapy (CBT), added to specialist medical care to be superior to adaptive pacing therapy added to specialist medical care and specialist medical care alone in improving fatigue and physical functioning for patients with chronic fatigue syndrome.1These findings were robust irrespective of how we defined the illness.1 In a mediational analysis2 we examined how the effective treatments worked. We noted that fear avoidance beliefs mediated both GET and CBT.2 This result was pertinent for both physical functioning and self-reported fatigue. It is also consistent with a review3 of the role of beliefs in chronic fatigue syndrome and fibromyalgia, which suggested that fear and avoidance of movement were associated with poorer outcomes.

Most correspondents make criticisms of the trial as a whole, which we have already addressed in detail, and which might reflect the apparent campaign to bring the robust findings of the trial into question.4, 5 McGrath reiterates the limitations of this mediator analysis, which we have already acknowledged in the Article.2 We intend to further explore multiple mediator effects and the potential effects of outcomes on mediators in future papers. Some correspondents suggest that objective outcomes are more important than self-report measures. In view of the subjective nature of fatigue and the overriding importance of the patients own judgement of their functioning, we believe that self-rated outcomes remain the most important ones. Although it is entirely understandable that some patients with chronic fatigue syndrome are cautious about engaging in activity and exercise, increasing those activities gradually offers both improved functioning and reduced fatigue in some patients. Our findings also suggest that better targeting of fearful beliefs in treatment may result in better outcomes.

PDW has done voluntary and paid consultancy work for the UK Government and a reinsurance company. TC has received royalties from Sheldon Press and Constable and Robinson. MS has done voluntary and paid consultancy work for the UK Government, has done consultancy work for an insurance company, and has received royalties from Oxford University Press. KAG and ARP declare no competing interests.



  • White, PD, Goldsmith, KA, Johnson, AL..., and on behalf of the PACE trial management group.Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet. 2011; 377:823–836
  • Chalder, T, Goldsmith, KA, White, PD, Sharpe, M, and Pickles, A. Rehabilitative therapies for chronic fatigue syndrome: a secondary mediation analysis of the PACE trial. Lancet Psychiatry. 2015;2: 141–152
  • Nijs, J, Roussel, N, Van Oosterwijck, J et al. Fear of movement and avoidance behaviour toward physical activity in chronic-fatigue syndrome and fibromyalgia: state of the art and implications for clinical practice. Clin Rheumatol. 2013; 32: 1121–1129
  • Lancet. Patients' power and PACE. Lancet. 2011; 377: 1808
  • White, PD, Chalder, T, and Sharpe, M. The planning, implementation and publication of a complex intervention trial for chronic fatigue syndrome: the PACE trial. BJPsych Bull. 2015; 39: 24–27
They also used the very same normal range criteria in their own revised definition for recovery in 2013.
 
Last edited:

Yogi

Senior Member
Messages
1,132
Here is the current FAQ's.


Pace Trial
Centre for Psychiatry
Project Lead Investigator: Peter White
Co-principal investigators: Professor T Chalder, Kings College London, Professor M Sharpe, University of Oxford


Previous Frequently Asked Questions (FAQs)
FAQ 1: written during the progress of the trial
FAQ 2: following publication of the main results (Lancet, 377,9768, 823-836, 5 March 2011)
FAQ 3: Mediation of treatments

Current FAQs

stringent procedures to ensure that those people with another diagnosis that would explain their fatigue were excluded. These included a full history and physical examination by a specialist doctor, ten blood tests and a urine test. All potential participants also underwent a standardised psychiatric interview. Together these procedures ensured that patients entering the trial were suffering from CFS.

Did you include people with ME?

Half (51 per cent) of trial participants met criteria for ME, as defined by the London criteria, which were based on the original description by the late Dr Melvin Ramsay, physician at the Royal Free Hospital. The trial results for people who met criteria for ME were the same as for those who did not.

here, and all newsletters were approved by the independent research ethics committee before publication.

For example, in this newsletter, there are six comments from patients about their treatments, but no specific treatment or therapy is named, and investigators were careful to print feedback from participants from all four treatment arms. We included these comments to try to encourage patients to consider entering the trial, in order to improve recruitment. However, by the time it was published, following ethical approval, all participants had been recruited. It would have been very unlikely that the newsletter could have biased participants as any influence on their ratings would affect all treatment arms equally.

The same newsletter also mentioned the publication of the UK National Institute for Health and Care Excellence guideline for the management of CFS (this institute is independent of the UK government). The guidelines were described in summary form, and the only reference made to individual therapies was in the following sentence: “The guidelines emphasise the importance of joint decision making and informed choice and recommended therapies include Cognitive Behavioural Therapy, Graded Exercise Therapy and Activity Management.” These three therapies were the ones being tested in the trial. It is therefore unlikely that it would lead to bias in the direction of one or other of these therapies

Cochrane Review group. Furthermore a number of published systematic reviews and meta-analyses have supported the findings. These include Whiting et al, 2001, Edmonds et al, 2004, Chambers et al, 2006, Malouff et al, 2008, Price et al, 2008,Castell et al, 2011, Larun et al, 2015, Marques et al, 2015 and Smith et al, 2015.

How effective were CBT and GET?
We concluded that both CBT and GET were more effective than APT and SMC and that the size of the effect was moderate. We drew these conclusions based on the size of their effect compared with APT and SMC and the proportions of participants who made a clinically useful reduction in fatigue and improvement in functioning.

Why did CBT and GET have similar effects? Is it just the effect of seeing a therapist?
Both CBT and GET were better than APT, so this suggests it was not simply due to the benefit of seeing a therapist. The better outcome may have been due to the active rehabilitative approach common to both CBT and GET, which encourages people gradually to do more. However, we have now analysed in more detail what makes these treatments work, and have reported these findings (also explained in a previous FAQ document).

Were the treatments safe?

We measured the safety of all the treatments in five separate ways, and found no significant differences in any of these measures among the different arms of the trial. We concluded that all these treatments are safe so long as they are delivered by similar healthcare professionals, who are trained and supervised to deliver these treatments in a similar way to the PACE trial.

Are the results applicable to those worst affected?
We do not know, as we did not study housebound participants. Results cannot therefore be extrapolated to those who are severely affected.

Does adaptive pacing therapy (APT) not work?
A minority of people who received APT did improve, but no more than the proportion who received SMC by itself. The majority of patients who received APT reported that they were satisfied with their therapy, but more than any other treatment APT was more likely to lead to worse physical functioning.

How is it possible that APT had the most satisfied group of patients but was the least effective therapy?
Satisfaction with a treatment is based on lots of things, such as how helpful the person found their therapist, and does not necessarily relate to its effectiveness. Patients can be satisfied that their therapist did their best, without the therapy itself improving symptoms and disability.

Did poor delivery of APT account for the findings?
We know the therapists delivered APT to a high standard and that APT was delivered as planned because of:

1. The high rates of patient satisfaction,
2. Recorded therapy sessions were consistent with the therapy manual when independently assessed,
3. The quality of the therapeutic relationships between patients and therapists, which were independently assessed, were as good with APT as with other therapies.

This suggests that it was the content of the therapy that was less effective, not the therapists or how it was delivered. It seems as though the adaptive nature of APT is not as effective as the rehabilitative approach common to both CBT and GET.

Would there be additional non-specific effects of seeing a therapist that could have influenced the results?
The non-specific effects of a therapist can be important. However, they would only account for the different outcomes between treatments if there was a difference in how the therapies were delivered between the treatment groups. It is unlikely that this was the case in the PACE trial. We ensured that all therapists were well trained and supervised, and that the total number of treatment sessions and time offered was the same across all therapies. Patients reported that they were similarly satisfied after all three therapies (APT, CBT and GET). Independent scrutineers of audio recordings of therapies reported that the therapies had been delivered as intended. In summary, it seems improbable that the differences between the therapy groups could be due to non-specific effects.

If the treatments received after the end of the trial and before the 2.5 year follow up were no longer allocated randomly, would this make the results harder to interpret?
Yes it did. After the end of the main study (one year post-treatment) participants were able to choose further treatments if they wished, thus breaking the original randomisation. In clinical trials, it is considered unethical to deny additional treatments to patients following the main phase of a trial if they are requested or needed.

In the findings of the 2.5 year follow up study it was noted that the originally randomly allocated treatment had often been supplemented by an additional treatment, and that this would limit what we could learn by comparing patients in their originally randomised treatment groups.

However, the main findings of the long-term follow were clear – that there was no deterioration from the one year improvements in patients originally allocated to CBT and GET.

Lancet, PLoS One and Lancet Psychiatry.

The distance participants could walk in six minutes was significantly improved following GET, compared to other treatments.

There were no significant differences in fitness, employment or welfare benefits between any of the treatments. In fact, the numbers of patients receiving welfare benefits went up in all treatment groups, perhaps because they were given a definite diagnosis, and received advice regarding eligibility for welfare benefits during the trial. Treatment manuals can be found here which include the advice regarding welfare benefits and work.

We interpreted these data in the light of their context and validity. For instance, we did not use employment status as a measure of recovery or improvement, because patients may not have been in employment before falling ill, or they may have lost their job because of being ill. Getting better and getting a job are not the same things, and being in employment depends on the prevailing state of the local economy as much as being fit for work.

Note: The above question has been answered elsewhere in 2008, 2011, 2013 (here and here) and 2015.

Could changes in the scoring of the two primary outcomes from the original trial protocol have caused bias?
The two primary outcomes for the trial in the original trial protocol were the SF-36 physical function sub-scale and the Chalder fatigue questionnaire. These were not changed.

However, as a trial like PACE takes many years to complete, discussion about how best to analyse the findings continued after it began, but before any data was analysed. These discussions led to changes in how we analysed the two primary outcomes (fatigue and physical function). The two independent oversight committees approved the changes. The detailed analysis plan, including these changes, was published, and these changes and the reasons for them were also described in the main paper.

The changes were

A. Simplifying the main analysis. Originally the analysis was going to use a more complex measure, which combined two ways to measure improvement (the number of patients who either exceeded a threshold score or who improved by more than 50 per cent). After careful consideration, it was decided that this composite measure would be very hard to interpret clinically, and would not allow the direct comparison of effectiveness between treatments. We therefore chose to compare mean (average) scores of each outcome measure. This is a better way to see which treatment works best on which outcome, and made the main findings easier to understand and interpret.

B. To use the Likert scoring method rather than the binary methods originally proposed for the fatigue questionnaire. This change was to achieve greater variability in the score and greater sensitivity to change. This is because the Likert method allows the questionnaire answers to have a score of 0, 1, 2 or 3 to indicate how much of a problem each fatigue factor is for the participant; 11 questions therefore gives a score that can range from 0 to 33. The binary method of scoring only considers a yes or no; 11 questions can therefore only produce a range of 0 to 11. Both Likert and binary methods of scoring have been described before and both are regularly used by other researchers.

There were no changes to the scoring method of the physical function scale

These changes have been explained in several publications (here and here), including explicit descriptions and justification within the main paper itself, the statistical analysis plan, and the trial website section of frequently asked questions, published in 2011.

Were some of the patients well when they entered the trial?
All patients entering the trial met the Oxford criteria for CFS and also had scores above thresholds of severity for fatigue and physical function. Some 13 per cent had scores within the normal population range (defined as within one standard deviation of the population means) for either one or other of fatigue and physical function. This is not the same as being well or as being ‘recovered’ (see below).

After an editorial suggested that having scores within the normal population range was consistent with recovery, the authors published a correction to clarify that this was not the case.

Did the trial look at recovery?
The main trial report did not address recovery. Recovery is a complex concept that is hard to define.

We did, however, look at recovery in an exploratory secondary analysis of different criteria and explored different ways of defining it.

Why did you change the criteria for determining recovery from the original protocol in the secondary analysis?
Over the long period from writing the original protocol to planning the analysis, we reconsidered our original definition of recovery. As a result, we tried to improve how we measured the concept of recovery and the different ways it can be defined.

For instance, we included those who felt “much” (and “very much”) better in their overall health as one of the five criteria that all had to be fulfilled to define recovery.

We also changed the thresholds for judging recovery on the two primary outcomes (fatigue and physical function) from the mean (average) for the population to the population mean plus a standard deviation from the mean, to better reflect the levels of fatigue and physical function found in the general population. This was informed by a recently published population study.

These changes were all made before the analysis occurred (i.e. they were pre-specified) and were fully described and explained in the paper itself. Furthermore, in the relevant paper we discussed the difficulties in measuring recovery, and showed how other ways of defining recovery could produce different results. The bottom line was that, however we defined recovery, significantly more patients had recovered after receivingCBT and GET than after other treatments.

Why did you not use more objective measures of recovery, such as employment or the distance walked in six minutes, in the secondary analysis?
We addressed this point in 2013 in correspondence that followed the paper. In summary, we did not think that being employed was the same as being recovered, since it was likely that some participants were not working before they became ill, or that they may have lost their job because of being ill. Many factors affect whether a person gains new employment.

We also explained that we did not use the distance walked in six minutes, as we were unable to use this measure in a way comparable to other studies, due to lack of space in some of our clinics and our concern not to exacerbate ill health in patients undertaking this test. Furthermore, some 18 per cent of participants did not undertake this test at follow up.

main results paper it was stated: "The effectiveness of behavioural treatments does not imply that the condition is psychological in nature."

The study tells us nothing about the cause of the illness, simply how effective different treatments are for helping people who have it.

The team that designed and ran the trial include many doctors and healthcare professionals who have worked and continue to work in chronic fatigue syndrome clinics, sometimes for many years.

They are aware of the serious and debilitating nature of chronic fatigue syndrome, and have witnessed in their clinics how the illness can ruin people’s lives and affect their families. There is no doubt in their minds that the illness can last for years and is a real and chronic condition, and they do not think CFS is ‘all in the mind’ or imaginary.

Some of those involved in the PACE trial also undertake research into the biological nature of the illness; research that has indicated that there are some biological abnormalities that have been found repeatedly in CFS.

How have you found a treatment to be useful when we do not know the cause of CFS?
There are very many examples in medicine where a treatment is developed for an illness before the cause of the illness is known. For example: quinine treating malaria, or digitalis (digoxin from the foxglove) helping heart failure. Treatments sometimes help in reversing the factors that keep someone unwell rather than addressing original causes. Digitalis is an example of that. CFS and ME are extremely debilitating and therefore there is a real need for treatment now. We are open minded about what research into the condition’s causes will reveal; in the meantime the PACE trial shows that CBT and GET can make a difference to patients’ lives today.

Why did not all participants improve?

Since approximately 6 out of 10 patients improved after either cognitive behavioural or graded exercise therapies, the results of this study are encouraging. But, as with treatments in most areas of medicine, there will be patients who do not respond to treatment. This underscores the need for continued research into this area.

Does the PACE trial say that CBT and GET are the only treatments for CFS?
The trial found CBT and GET to be moderately helpful and also that they do not benefit everyone. All patients also received specialist medical care, which might involve being prescribed medicines to help symptoms such as insomnia or pain.

It has always been recognised that more research is needed to find other treatments that help. This was recently stated in the results of the 2.5 year follow up when it was noted that in all of the treatment groups some patients remained unwell at long-term follow-up. This was described as “an observation that reminds us that better treatments are still needed for patients with this chronically disabling disorder.”

Who funded the PACE trial?
The trial was funded by the Medical Research Council (MRC), the Department of Health, the Department of Work and Pensions and the Scottish Chief Scientist Office.

Would there have been any conflicts of interest, for example, the investigators’ past involvement in insurance companies?
No insurance company was involved in any aspect of the trial. There were some 19 investigators, three of whom had done consultancy work at various times for insurance companies. This consultancy work was not related to the conduct of the research. Furthermore, it is not clear how this would be a conflict of interest; other than, the interest shared by patients and health services in finding a treatment that helps patients.

Following the trend to report all interests, whether judged to be conflicting or not, all sources of income were listed as potential conflicts of interest in the relevant papers.

The patient information sheet informed all potential participants as to which organisations had funded the research, which is consistent with ethical guidelines.
 
Last edited:

Dolphin

Senior Member
Messages
17,567
Would there have been any conflicts of interest, for example, the investigators’ past involvement in insurance companies?
No insurance company was involved in any aspect of the trial. There were some 19 investigators, three of whom had done consultancy work at various times for insurance companies. This consultancy work was not related to the conduct of the research. Furthermore, it is not clear how this would be a conflict of interest; other than, the interest shared by patients and health services in finding a treatment that helps patients.

Ellie43 in posts in this thread http://forums.moneysavingexpert.com/showthread.php?t=2356683 describes how Peter White was involved in having her claim turned down.

e.g.
that didn't stop PW advising my insurer that my claim should be refused until I undertook CBT/GET again.

Turn X number of people down and a percentage of people give up in my experience, saving the insurance company (or Department of Work and Pensions) money. However they wouldn't be able to turn down claims for this reason if it was felt that CBT or GET were not effective and safe. So having the PACE Trial say that CBT and GET are effective and safe can enable insurance companies to turn down some claims and very likely reduce the number of claims they have to pay.
 
Last edited:

wdb

Senior Member
Messages
1,392
Location
London
Is it a problem that participants were not blinded to the treatments being received?
Both the therapists and patients knew what treatments they were being given. This is unavoidable for trials of rehabilitative treatments in which the patient is an active participant.

Maybe it's unavoidable but that doesn't answer the question IS IT A PROBLEM ? (yes it is a major problem)

Was the treatment effect due to some participants getting more attention than others?
This is very unlikely as the three additional therapies were closely matched for amount of patient contact.

So they were matched for patient contact but were they also closely matched for the degree to which each therapy attempts to alter perceptions of illness severity ? No not by a long shot and this is a much bigger deal, in fact it is literally how the outcome is measured.

Was the treatment effect due to participants expecting to get better with CBT or GET?
This is also very unlikely as we measured participants’ expectations of their allocated treatment, after they knew which one they were getting and before they started it. This indicated that patients expected CBT to be least likely to be helpful...

So you acknowledge expectation can be important, why didn't you measure it again after the start of the trial or after manuals had been distributed and read. Was there any attempt to assess if the glowing praise of some therapies and their effectiveness contained within the treatment manuals given to participants may have reversed earlier expectations ?
 

Yogi

Senior Member
Messages
1,132
This is a Masterclass in Spin, obfuscation, waffle, weasle words and lots of speculation and lots of use of "maybe", "perhaps" etc in trying to defend their fraudulent trial.

It has Sir Simon "thing of beauty" Wessely's fingerprints all over it.

Is this the best they can come up with after nearly one year of David Tuller's original investigation. I am sure we can take rip apart each FAQ in detail in due course.

It is just PR for people who are not knowledgeable about the fraudulent PACE trial.

Just answer Tuller's questions directly and no need to defend the indefensible but just retract this "piece of crap".
 
Last edited:

Yogi

Senior Member
Messages
1,132
Ellie43 in posts in this thread http://forums.moneysavingexpert.com/showthread.php?t=2356683 describes how Peter White was involved in having her claim turned down.

e.g.


Turn X number of people down and a percentage of people give up in my experience, saving the insurance company (or Department of Work and Pensions) money. However they wouldn't be able to turn down claims for this reason if it was felt that CBT or GET were not effective and safe. So having the PACE Trial say that CBT and GET are effective and safe can enable insurance companies to turn down some claims and very likely reduce the number of claims they have to pay.


Just to add Peter White is not a CMO for any ordinary insurer but a re-insurer.

MASSIVE DIFFERENCE that cannot be overemphasised!

Effectively it is like having an undisclosed conflict of interest of dozens or even hundreds of insurers and possibly with the vast majority of insurers in UK, Europe and globally. How many re-insure with Peter White's company is unclear. Why does he not add that to his FAQ.

Here is a just a list of UK insurers (members of ABI) and there are 210 members.

https://www.abi.org.uk/About/ABI-members
 
Last edited:

Sean

Senior Member
Messages
7,378
Is it a problem that participants were not blinded to the treatments being received?
Both the therapists and patients knew what treatments they were being given. This is unavoidable for trials of rehabilitative treatments in which the patient is an active participant.
Maybe it's unavoidable but that doesn't answer the question IS IT A PROBLEM ? (yes it is a major problem)
If this is an inherent limitation, fine. But they fail to follow through and accept that it also means that the reliability of their results is much lower, and hence the claims they can make based on that data must also be downgraded.
 
Last edited:

A.B.

Senior Member
Messages
3,780
Psychiatry needs to start doing real science instead of nonsense unblinded studies without objective outcomes and/or bad control groups.

Of course real science means they would suddenly find out that most of their interventions don't work.
 

Wolfiness

Activity Level 0
Messages
482
Location
UK
My current most frequently asked question is re the protocol changes. This is a collection of experts who have devoted their professional lives to studying rehabilitative therapies for ME. How did they start a huge formal trial with so little apparent notion of how to assess their results properly that they had to change all their methods half way through?! PACE is not a pile but an endlessly yielding kaleidoscope of crap.
 
Last edited: